GleamWall
中文EN

BHC Bausch Health Companies Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 885590 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.8%
TTM net income YoY-332.3%
TTM EPS YoY-332.0%
Revenue 3-yr CAGR9.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin11.2%
Net margin-7.6%
FCF margin16.8%
EBITDA margin21.6%

Returns

ROE—
ROA-3.2%
ROIC (approx.)5.5%
Asset turnover0.42x

Leverage & solvency

Liabilities / assets101.3%
Debt / equity—
Current ratio1.56x
Interest coverage0.78x

Cash quality & payout

Operating cash flow / net income-2.63x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.94B$2.85B$2.52B$2.80B$2.68B$2.53B$2.26B$2.56B
R&D expense$141.00M$173.00M$163.00M$161.00M$166.00M$159.00M$143.00M$163.00M
SG&A expense$834.00M$907.00M$861.00M$882.00M$795.00M$894.00M$867.00M$820.00M
Operating income$983.00M$740.00M-$950.00M$474.00M$619.00M$444.00M$276.00M$558.00M
Interest expense$398.00M$396.00M$402.00M$397.00M$412.00M$465.00M$330.00M$337.00M
Pretax income$597.00M$348.00M-$1.35B$56.00M$218.00M$140.00M-$47.00M$209.00M
Income tax$151.00M$88.00M$77.00M$159.00M$37.00M$12.00M$39.00M$111.00M
Net income$436.00M$258.00M-$1.42B-$112.00M$179.00M$148.00M-$58.00M$93.00M
EBITDA$1.27B$1.02B-$655.00M$764.00M$925.00M$751.00M$581.00M$865.00M
EPS (basic)1.160.69-3.82—0.480.40-0.16—
EPS (diluted)1.150.68-3.82—0.480.40-0.16—
Weighted avg. shares (diluted)380.70M378.10M372.80M—375.50M373.10M369.60M—
Balance sheet
Cash & equivalents$2.48B$1.82B$1.30B$1.31B$1.31B$1.73B$1.13B$1.20B
Receivables$2.53B$2.26B$2.19B$2.35B$2.42B$2.21B$2.07B$2.14B
Inventory$1.59B$1.60B$1.60B$1.63B$1.60B$1.66B$1.61B$1.59B
Current assets$7.41B$6.52B$5.98B$6.16B$6.25B$6.51B$5.73B$5.77B
PP&E, net$2.11B$2.10B$2.10B$2.07B$2.03B$1.99B$1.88B$1.78B
Goodwill$9.77B$9.79B$9.81B$11.27B$11.29B$11.30B$11.15B$11.09B
Intangibles$3.97B$4.18B$4.40B$4.64B$4.83B$5.05B$5.30B$5.55B
Total assets$25.48B$24.79B$24.50B$26.37B$26.82B$27.27B$26.42B$26.52B
Current liabilities$4.75B$4.54B$4.53B$4.18B$4.79B$4.97B$4.26B$6.75B
Short-term debt$866.00M$866.00M$889.00M$225.00M$579.00M$879.00M$282.00M$2.67B
Long-term debt$19.77B$19.88B$19.88B$20.59B$20.46B$20.86B$21.23B$18.94B
Total debt$20.64B$20.74B$20.76B$20.82B$21.04B$21.74B$21.51B$21.62B
Total liabilities$25.82B$25.60B$25.58B$25.99B$26.47B$27.12B$26.66B$26.84B
Shareholders' equity-$1.33B-$1.77B-$2.06B-$554.00M-$565.00M-$764.00M-$1.18B-$1.28B
Net debt$18.15B$18.92B$19.46B$19.51B$19.73B$20.01B$20.38B$20.41B
Shares outstanding374.25M373.90M373.46M370.53M370.47M369.75M369.54M367.84M
Cash flow statement
Operating cash flow$814.00M$670.00M$230.00M$495.00M$405.00M$289.00M$211.00M$601.00M
Capital expenditure$66.00M$77.00M$109.00M$92.00M$91.00M$99.00M$115.00M$106.00M
Free cash flow$748.00M$593.00M$121.00M$403.00M$314.00M$190.00M$96.00M$495.00M
Investing cash flow-$83.00M-$93.00M-$139.00M-$282.00M-$83.00M-$100.00M-$130.00M-$200.00M
Financing cash flow-$80.00M-$49.00M-$100.00M-$235.00M-$719.00M$358.00M-$146.00M$85.00M
Depreciation & amortization$284.00M$281.00M$295.00M$290.00M$306.00M$307.00M$305.00M$307.00M
Stock-based compensation$52.00M$54.00M$52.00M$84.00M$43.00M$46.00M$43.00M$43.00M

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.